2021-11-29 07:03:43 ADGI Adagio Therapeutics
11/29/21 11/2907:03 11/29/2107:03 | Adagio Therapeutics prvides information of ADG20 to address Omicron variantAdagio Therapeutics provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron SARS-CoV-2 variant, and other known variants of concern. ADG20 is an investigational monoclonal antibody product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year in a single injection. Given the significant potential health crisis resulting from the emergence of Omicron, Adagio is undertaking a number of activities to support ADG20's utility in addressing this newly emerged variant of concern, including: Conducting in vitro studies to evaluate the expected binding and neutralizing activity of ADG20 against Omicron. Initial data from these studies is anticipated by the end of the year; and Recruiting patients in Adagio's Phase 2/3 COVID-19 treatment trial, known as STAMP, across several clinical sites in South Africa in an effort to generate clinical data for ADG20 against infections due to the Omicron variant. Based on the data being generated, Adagio plans to engage with health authorities and government agencies to accelerate development and supply of ADG20 to combat SARS-CoV-2 and its variants of concern. The neutralizing antibody response induced by SARS-CoV-2 infection and vaccination is dominated by three classes of receptor binding domain- directed antibodies , which often share common escape mutations. The newly emerged Omicron variant identified in South Africa contains mutations associated with resistance to a large proportion of these commonly elicited antibodies, which may be due to immune pressure on these antigenic sites. Data for most antibodies available under EUA or in late-stage clinical development show they target one of these three dominant antigenic regions within the RBD. In vitro studies have shown that ADG20 binds to a highly conserved epitope within the RBD that is not targeted by any of the common classes of neutralizing antibodies induced by SARS-CoV-2 infection and vaccination. Thus, unlike many other clinical-stage antibodies, which were isolated from COVID-19 patients and recognize epitopes that are also targeted by endogenous neutralizing antibodies, there is limited immune pressure on the ADG20 binding site. The ADG20 epitope has remained conserved in 99.99% of the nearly 4 million full length SARS-CoV-2 viral sequences deposited in the GISAID database as of October 15, 2021, and, as shown in in vitro studies, ADG20 retains activity against prior variants of concern including Alpha, Beta, Delta, and Gamma. For the Omicron variant, none of the mutations present in the spike protein are associated with escape from ADG20 neutralization. Based on published epitope mapping and structural studies, Adagio anticipates that ADG20 will retain neutralizing activity against the Omicron variant whereas other mAb products may lose substantial activity against this variant. Previously disclosed in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the recently emerged Lambda, Mu and Delta plus variants. Notably, findings from these in vitro studies showed that ADG20 demonstrated potent neutralizing activity against all SARS-CoV-2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under EUA or in late-stage development. |
|
---|
Downgrade
|
Columbus McKinnon downgraded to Hold at Craig-Hallum on lack of catalysts »
14:52 05/25/22 05/2514:52 05/25/2214:52
CMCO
Columbus McKinnon
Craig-Hallum analyst Greg… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
BASF price target lowered to EUR 62 from EUR 64 at Morgan Stanley »
14:51 05/25/22 05/2514:51 05/25/2214:51
BASFY
BASF
Morgan Stanley analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Aurubis price target lowered to EUR 87 from EUR 95 at Morgan Stanley »
14:51 05/25/22 05/2514:51 05/25/2214:51
AIAGY
Aurubis
Morgan Stanley analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Prosus price target lowered to EUR 90 from EUR 110 at Citi »
14:50 05/25/22 05/2514:50 05/25/2214:50
PROSY
Prosus
Citi analyst Catherine… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
EOCL award watershed moment for BlackSky, GIS industry, says Benchmark »
14:50 05/25/22 05/2514:50 05/25/2214:50
BKSY
BlackSky
Planet Labs
Maxar Technologies
Benchmark analyst Josh… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Columbus McKinnon downgraded to Hold from Buy at Craig-Hallum »
14:49 05/25/22 05/2514:49 05/25/2214:49
CMCO
Columbus McKinnon
Craig-Hallum analyst Greg… Story temporarily locked. ShowHide Related Items >><<
|
Options
|
ZTO Express options imply 7.0% move in share price post-earnings »
14:49 05/25/22 05/2514:49 05/25/2214:49
ZTO
ZTO Express
Pre-earnings options… Story temporarily locked. ShowHide Related Items >><<
|
General news
|
Treasury Action: yields are a little richer »
14:35 05/25/22 05/2514:35 05/25/2214:35
$ECON
Economic Data
Treasury Action: yields… Story temporarily locked. ShowHide Related Items >><<
|
Options
|
Box options imply 7.5% move in share price post-earnings »
14:34 05/25/22 05/2514:34 05/25/2214:34
BOX
Box
Pre-earnings options… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Philips price target lowered to EUR 21.30 from EUR 26.50 at JPMorgan »
14:24 05/25/22 05/2514:24 05/25/2214:24
PHG
Philips
JPMorgan analyst David… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Mitchells & Butlers price target lowered to 225 GBp from 276 GBp at JPMorgan »
14:23 05/25/22 05/2514:23 05/25/2214:23
MBPFF
Mitchells & Butlers
JPMorgan analyst Ted… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Kingfisher price target lowered to 245 GBp from 255 GBp at JPMorgan »
14:23 05/25/22 05/2514:23 05/25/2214:23
KGFHY
Kingfisher
JPMorgan analyst Georgina… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Glencore price target lowered to ZAR 12,800 from ZAR 13,200 at JPMorgan »
14:22 05/25/22 05/2514:22 05/25/2214:22
GLNCY
Glencore
JPMorgan analyst Dominic… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Darktrace price target lowered to 320 GBp from 400 GBp at JPMorgan »
14:22 05/25/22 05/2514:22 05/25/2214:22
DRKTF
Darktrace
JPMorgan analyst Varun… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Auto Trader Group price target lowered to 516 GBp from 586 GBp at JPMorgan »
14:21 05/25/22 05/2514:21 05/25/2214:21
ATDRY
Auto Trader Group
JPMorgan analyst Marcus… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Saipem price target raised to EUR 6.20 from EUR 1.30 at JPMorgan »
14:20 05/25/22 05/2514:20 05/25/2214:20
SAPMY
Saipem
JPMorgan analyst James… Story temporarily locked. ShowHide Related Items >><<
|
Options
|
Guess options imply 10.8% move in share price post-earnings »
14:19 05/25/22 05/2514:19 05/25/2214:19
GES
Guess
Pre-earnings options… Story temporarily locked. ShowHide Related Items >><<
|
On The Fly
|
Here's what Wall Street experts are saying about Alibaba ahead of earnings »
14:17 05/25/22 05/2514:17 05/25/2214:17
BABA
Alibaba
Alibaba (BABA) is… ShowHide Related Items >><<
|
Hot Stocks
|
TowneBank raises quarterly cash dividend to 23c per share »
14:17 05/25/22 05/2514:17 05/25/2214:17
TOWN
TowneBank
TowneBank announced that… Story temporarily locked. ShowHide Related Items >><<
|
Technical Analysis
|
NASDAQ market internals summary »
14:17 05/25/22 05/2514:17 05/25/2214:17
$NSD
NASDAQ Market Internals
Volume is above average… Story temporarily locked. ShowHide Related Items >><<
|
Technical Analysis
| Volume is above average… Story temporarily locked. ShowHide Related Items >><<
|
General news
|
FOMC minutes were largely as analysts expected »
14:15 05/25/22 05/2514:15 05/25/2214:15
$ECON
Economic Data
FOMC minutes were largely… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Canaccord keeps Buy on Maxar Technologies, raises price target to $40 »
14:10 05/25/22 05/2514:10 05/25/2214:10
MAXR
Maxar Technologies
Canaccord analyst Austin… Story temporarily locked. ShowHide Related Items >><<
|
General news
|
Fed says all members voted in favor of plan to reduce size of balance sheet »
14:05 05/25/22 05/2514:05 05/25/2214:05
$ECON
Economic Data
SPDR S&P 500 ETF Trust
S&P 500
Minutes from the last… Story temporarily locked. ShowHide Related Items >><<
|
Options
|
Nutanix options imply 12.9% move in share price post-earnings »
14:04 05/25/22 05/2514:04 05/25/2214:04
NTNX
Nutanix
Pre-earnings options… Story temporarily locked. ShowHide Related Items >><<
|